Bobak Azamian, M.D., Ph.D.

Bobak Azamian, M.D., Ph.D.

President, Chief Executive Officer and Board ChairmanatTarsus Pharmaceuticals· In proxies 2022–2025

Pay in FY2025-16% from the year before · Tarsus Pharmaceuticals stock +47.9% the same year

Bobak Azamian, M.D., Ph.D. was paid $6.6M in FY2025 (Dec), down 16%. Tarsus Pharmaceuticals stock rose 47.9% that year.

Pay$100 in the stock at the end of FY21 → $364
Pay is from the Summary Compensation Table of each Tarsus Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Tarsus PharmaceuticalsPublic company · 4 yr
    • President, Chief Executive Officer and Board Chairman2022 – Present · 4 yrStock in role +182%
  2. Corporate Governance—DirectorsPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?